DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients

Lukas Vrba, Marc M. Oshiro, Samuel S. Kim, Linda L. Garland, Crystal Placencia, Daruka Mahadevan, Mark A. Nelson, Bernard W. Futscher

Research output: Contribution to journalArticle

Abstract

Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers. Using DNA methylation specific qPCR we now clinically tested a group of these cancer-specific loci on cell-free DNA (cfDNA) extracted from the plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) patients. These DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC = 0.956), and furthermore, the signal from the markers correlates with tumour size and decreases after surgical resection of lung tumours. Presented observations suggest the clinical value of these DNA methylation biomarkers for NSCLC diagnostics and monitoring. Since we successfully validated the biomarkers using independent DNA methylation data from multiple additional common carcinoma cohorts (bladder, breast, colorectal, oesophageal, head and neck, pancreatic or prostate cancer) we predict that these DNA methylation biomarkers will detect additional carcinoma types from plasma samples as well.

Original languageEnglish (US)
JournalEpigenetics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

DNA Methylation
Non-Small Cell Lung Carcinoma
Computer Simulation
Biomarkers
Biopsy
Neoplasms
Carcinoma
Head and Neck Neoplasms
Pancreatic Neoplasms
Epigenomics
Area Under Curve
Lung Neoplasms
Prostatic Neoplasms
Urinary Bladder
Breast
Sensitivity and Specificity
Lung
DNA

Keywords

  • biomarker
  • Cancer marker
  • cfDNA
  • DNA methylation
  • liquid biopsy
  • NSCLC

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients. / Vrba, Lukas; Oshiro, Marc M.; Kim, Samuel S.; Garland, Linda L.; Placencia, Crystal; Mahadevan, Daruka; Nelson, Mark A.; Futscher, Bernard W.

In: Epigenetics, 01.01.2019.

Research output: Contribution to journalArticle

@article{c71ea27b0e494316b5121e531415fc7b,
title = "DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients",
abstract = "Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers. Using DNA methylation specific qPCR we now clinically tested a group of these cancer-specific loci on cell-free DNA (cfDNA) extracted from the plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) patients. These DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC = 0.956), and furthermore, the signal from the markers correlates with tumour size and decreases after surgical resection of lung tumours. Presented observations suggest the clinical value of these DNA methylation biomarkers for NSCLC diagnostics and monitoring. Since we successfully validated the biomarkers using independent DNA methylation data from multiple additional common carcinoma cohorts (bladder, breast, colorectal, oesophageal, head and neck, pancreatic or prostate cancer) we predict that these DNA methylation biomarkers will detect additional carcinoma types from plasma samples as well.",
keywords = "biomarker, Cancer marker, cfDNA, DNA methylation, liquid biopsy, NSCLC",
author = "Lukas Vrba and Oshiro, {Marc M.} and Kim, {Samuel S.} and Garland, {Linda L.} and Crystal Placencia and Daruka Mahadevan and Nelson, {Mark A.} and Futscher, {Bernard W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/15592294.2019.1695333",
language = "English (US)",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients

AU - Vrba, Lukas

AU - Oshiro, Marc M.

AU - Kim, Samuel S.

AU - Garland, Linda L.

AU - Placencia, Crystal

AU - Mahadevan, Daruka

AU - Nelson, Mark A.

AU - Futscher, Bernard W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers. Using DNA methylation specific qPCR we now clinically tested a group of these cancer-specific loci on cell-free DNA (cfDNA) extracted from the plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) patients. These DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC = 0.956), and furthermore, the signal from the markers correlates with tumour size and decreases after surgical resection of lung tumours. Presented observations suggest the clinical value of these DNA methylation biomarkers for NSCLC diagnostics and monitoring. Since we successfully validated the biomarkers using independent DNA methylation data from multiple additional common carcinoma cohorts (bladder, breast, colorectal, oesophageal, head and neck, pancreatic or prostate cancer) we predict that these DNA methylation biomarkers will detect additional carcinoma types from plasma samples as well.

AB - Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers. Using DNA methylation specific qPCR we now clinically tested a group of these cancer-specific loci on cell-free DNA (cfDNA) extracted from the plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) patients. These DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC = 0.956), and furthermore, the signal from the markers correlates with tumour size and decreases after surgical resection of lung tumours. Presented observations suggest the clinical value of these DNA methylation biomarkers for NSCLC diagnostics and monitoring. Since we successfully validated the biomarkers using independent DNA methylation data from multiple additional common carcinoma cohorts (bladder, breast, colorectal, oesophageal, head and neck, pancreatic or prostate cancer) we predict that these DNA methylation biomarkers will detect additional carcinoma types from plasma samples as well.

KW - biomarker

KW - Cancer marker

KW - cfDNA

KW - DNA methylation

KW - liquid biopsy

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85075761743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075761743&partnerID=8YFLogxK

U2 - 10.1080/15592294.2019.1695333

DO - 10.1080/15592294.2019.1695333

M3 - Article

C2 - 31775567

AN - SCOPUS:85075761743

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

ER -